Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.
- Published: December 2010
The present Competitive Intelligence Report provides a competitor evaluation in the field of molecules used to treat diabetes as of March 2007.
The competitor evaluation of Molecules to treat diabetes compiles parts of our Competitor Analysis Series which previously have been published in R&D Pipeline News, vol.3, 2007.
Information is provided on:
Drug Codes, Target / Mechanism of Action, Class of Compound, Company, Product Category Indication, R&D Stage and additional comments with a hyperlink leading to the source of information.
Chapter I: Insulin Insulin Market: Sales 2006 Inhaled Insulin Nasal Insulin Transdermal Insulin Oral Insulin Engineered Insulin Long-Acting Insulin Follow-On Insulin Chapter II: PPAR Agonists 1st Generation PPAR Gamma Agonists Next Generation PPAR Gamma Agonists PPAR Alpha Agonists (Fibrate Type) PPAR Alpha Agonists Discontinued PPAR Alpha Agonists Dual PPAR Alpha And Gamma Agonists Discontinued Dual PPAR Alpha ? Gamma Agonists Triple PPAR Alpha, Gamma & Delta (Pan) Agonists Chapter III: DPP-IV DPP-IV DPP-IV Discontinued or No Further Activities Chapter IV: GLP-1 Chapter V: SGLT Inhibitors Chapter IV: Emerging Diabetes Drugs About la Merie Business Intelligence
The present Competitive Intelligence Report provides a competitor evaluation in the field of molecules used to treat diabetes as of March 2007